Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : Pfizer Inc
Homme Max 99 ans
Pfizer Inc.235 East 42nd Street, New York, NY 10017
MAJ Il y a 4 ans
A MULTIPLE DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND EFFICACY OF SUBCUTANEOUS AND/OR INTRAVENOUS PF-06741086 IN SUBJECTS WITH SEVERE HEMOPHILIA ESTUDIO CON MÚLTIPLES DOSIS PARA EVALUAR LA SEGURIDAD, LA TOLERABILIDAD, LA FARMACOCINÉTICA, LA FARMACODINÁMICA Y LA EFICACIA DE LA ADMINISTRACIÓN DE PF-06741086 POR VÍA SUBCUTÁNEA O INTRAVENOSA EN SUJETOS CON HEMOFILIA GRAVE
To determine the safety and tolerability of multiple doses of PF-06741086 administered to severe hemophilia A and B subjects. Determinar la seguridad y la tolerabilidad de múltiples dosis de PF ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Pfizer Inc
MAJ Il y a 4 ans
A Multicenter Phase 3 Randomized, Open-Label Study of Bosutinib versus Imatinib in Adult Patients with Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia
To compare the proportion of patients demonstrating Major Molecular Response (MMR) at 12 months (48 weeks) in the bosutinib arm with that of the imatinib arm in newly diagnosed Philadelphia chromosome...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Pfizer Inc.235 East 42nd Street, New York, NY 10017
MAJ Il y a 4 ans
PHASE 3, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF 2 DOSES OF CP 690,550 MONOTHERAPY IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS
1. To compare the efficacy of CP 690,550, as monotherapy, in doses of 5 mg BID and 10 mg BID versus placebo for the treatment of signs and symptoms of rheumatoid arthritis (RA), in subjects with RA wh...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Pfizer Inc., 235 East 42nd Street, New York, NY 10017, USA
MAJ Il y a 4 ans
Phase 1/2 study evaluating the safety and anti-tumor activity of PD 0332991 in combination with Velcade and dexamethasone in patients with multiple myeloma
Phase I To determine the maximum tolerated dose (MTD) and RP2D of PD 0332991 in combination with bortezomib and dexamethasone Phase II To evaluate the anti-tumor activity of PD 0332991 in com...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Pfizer Inc.235 East 42nd Street, New York, NY 10017
MAJ Il y a 4 ans
A clinical trial to evaluate whether a potential new drug is an effective and safe way to make damaged kidneys work better in patients with type II diabetes
To evaluate the efficacy of PF-00489791 in the reduction of albuminuria in subjects with type 2 diabetes and overt nephropathy.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Pfizer Inc, 235 East 42nd Street, New York, New York 10017
MAJ Il y a 4 ans
A study to investigate the efficacy of CP-690,550 in subjects with moderate to severe ulcerative colitis
To demonstrate the efficacy of CP 690,550 in inducing remission in subjects with moderately to severely active ulcerative colitis.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Pfizer Inc.235 East 42nd Street, New York, NY 10017
MAJ Il y a 4 ans
A study to find out how long a person continues to have antibodies against Meningococcal B disease following vaccination
To describe the immunogenicity of bivalent rLP2086 as determined by hSBA titers to primary test strains at approximately 6, 12, 18, 24, 36, and 48 months after the last dose (second or third dose) of ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Pfizer Inc. NYO-685-21-14,685 3rd Avenue, NEW YORK, NY 10017. US
MAJ Il y a 4 ans
12-WEEK, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF FESOTERODINE IN COMPARISON TO TOLTERODINE ER IN PATIENTS WITH OVERACTIVE BLADDER
To compare the efficacy of fesoterodine to placebo and tolterodine ER in subjects with overactive bladder after 12 weeks of treatment.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Pfizer Inc. 235 East 42nd Street, New York, 10017
MAJ Il y a 4 ans
A PHASE 3, MULTI-SITE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF THE EFFICACY AND SAFETY OF 2 ORAL DOSES OF CP-690,550 IN SUBJECTS WITH MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS
• To compare the efficacy of CP-690,550 (5 mg BID and 10 mg BID) versus placebo for the reduction in severity of plaque psoriasis after 16 weeks of treatment in subjects with moderate to severe chroni...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Pfizer Inc.235 East 42nd Street, New York, NY 10017
MAJ Il y a 4 ans
A STUDY OF THE MAINTENANCE OF EFFICACY OF ETANERCEPT PLUS DMARD(S) COMPARED WITH DMARD(S) ALONE IN SUBJECTS WITH RHEUMATOID ARTHRITIS AFTER ACHIEVING AN ADEQUATE RESPONSE WITH ETANERCEPT PLUS DMARD(S) VIZSGÁLAT AZ ETANERCEPT PLUSZ DMARD(OK) ÉS AZ ÖNMAGUKBAN ALKALMAZOTT DMARD(OK) FENNTARTOTT HATÁSOSSÁGÁNAK ÉRTÉKELÉSÉRE RHEUMATOID ARTHRITISBEN SZENVEDŐ BETEGEKNÉL, AKIK MEGFELELŐEN REAGÁLTAK AZ ETANERCEPT PLUSZ DMARD KEZELÉSRE
To compare the maintenance of efficacy of the combination of ETN 50 mg once weekly plus MTX (± other DMARDs) therapy with that of MTX (± other DMARDs) at Week 52 in subjects with moderately to severel...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Précédent
7
8
9
10
11
12
13
14
15
16
Suivant